Onyia Jude sold $1.8M of NBIX
Onyia Jude (Chief Scientific Officer) sold 11,000 shares of NEUROCRINE BIOSCIENCES INC (NBIX) at $160.25 ($1.76M total) on 2026-06-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The trade can influence short-term sentiment and intraday order flow, but it is not a fundamental update (no guidance, trial, or deal information provided).
Market read
A single insider sale under a 10b5-1 plan is typically a low-signal event for fundamentals, with at most modest sentiment impact.
What to watch
The article provides only the sale details (size, price, post-sale holdings) and no context on whether other insiders or institutions are buying/selling concurrently.
Background
SEC Form 4 insider transaction disclosures report officer/director/10%+ owner trades; 10b5-1 plans are pre-scheduled to reduce insider-timing concerns.
Ticker impact
Neurocrine Biosciences’ Chief Scientific Officer sold 11,000 shares in an open-market transaction disclosed via SEC Form 4.
Likely limited immediate price impact; any effect is more sentiment/flow-driven than fundamental.
Form 4 shows a scheduled 10b5-1 sale (not discretionary timing), with no accompanying operational or financial catalyst in the article.
Market effects
Minimal; this is company-specific insider activity with no stated sector-wide catalyst.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, traders may overreact; the disclosure may be routine rather than a bearish signal.
Key entities
- issuerNeurocrine Biosciences, Inc.
Subject of the Form 4 insider sale by its Chief Scientific Officer.
- insiderOnyia Jude
Chief Scientific Officer who sold 11,000 shares on 2026-06-01 under a 10b5-1 plan.
